CRISPR Therapeutics (NASDAQ:CRSP) Director Kurt Von Emster sold 250,000 shares of the business’s stock in a transaction on Friday, May 11th. The shares were sold at an average price of $52.84, for a total transaction of $13,210,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Kurt Von Emster also recently made the following trade(s):

  • On Monday, May 14th, Kurt Von Emster sold 650,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $54.39, for a total transaction of $35,353,500.00.

CRSP opened at $65.40 on Friday. CRISPR Therapeutics has a 1-year low of $56.38 and a 1-year high of $59.00. The firm has a market capitalization of $2.73 billion, a price-to-earnings ratio of -38.25 and a beta of 3.58.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Wednesday, May 9th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.05. CRISPR Therapeutics had a negative net margin of 189.60% and a negative return on equity of 35.18%. The firm had revenue of $1.36 million during the quarter, compared to the consensus estimate of $3.64 million. During the same period in the previous year, the firm posted ($0.54) earnings per share. The business’s revenue was down 49.6% compared to the same quarter last year. equities research analysts predict that CRISPR Therapeutics will post -2.6 EPS for the current year.

Several equities analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of CRISPR Therapeutics from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a report on Friday, May 11th. TheStreet lowered shares of CRISPR Therapeutics from a “c” rating to a “d+” rating in a report on Friday, May 11th. BidaskClub upgraded shares of CRISPR Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Monday. Chardan Capital boosted their target price on shares of CRISPR Therapeutics from $25.00 to $72.50 and gave the company a “buy” rating in a report on Tuesday. Finally, ValuEngine raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. Four analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $64.28.

Institutional investors and hedge funds have recently bought and sold shares of the business. Ladenburg Thalmann Financial Services Inc. increased its stake in CRISPR Therapeutics by 334.0% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,054 shares of the company’s stock valued at $186,000 after purchasing an additional 3,120 shares in the last quarter. M&T Bank Corp bought a new stake in CRISPR Therapeutics in the first quarter valued at $202,000. Element Capital Management LLC bought a new stake in CRISPR Therapeutics in the first quarter valued at $210,000. BBR Partners LLC bought a new stake in shares of CRISPR Therapeutics during the first quarter worth about $229,000. Finally, Creative Planning bought a new stake in shares of CRISPR Therapeutics during the fourth quarter worth about $243,000. 36.73% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

Insider Buying and Selling by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.